Construction of METHFR shRNA/5-fluorouracil co-loaded folate-targeted chitosan polymeric nanoparticles and its anti-carcinoma effect on gastric cells growth
Source abstract
Abstract
PEGylated and folate-targeted chitosan polymeric nanoparticles (FPNs) for the treatment of gastric carcinoma were prepared successfully. OQC-anchored folate conjugates were synthesized and used in assembling FPNs nano-system for enhancing intracellular uptake against folate receptor overexpressing cancer cells. The results indicated that folate-targeted chitosan polymeric nanoparticles (CPNs) can reverse drug-resistant SGC-7901 cells of 5-fluorouracil (5-FU) compared with non-targeted CPNs. Increased therapeutic efficiency of 5-FU/METHFR shRNA co-loaded PNs were also tested in SGC-7901 cells and compaed with 5-FU or METHFR shRNA in solution, which was associated with increased cell inhibition function for single drug group and synergistic effects of 5-FU and METHFR shRNA at 2.0 µg/mL FPNs concentration. In addition, the cell accumulation levels of 5-FU in SGC-7901 cells was time dependent for these nanoparticles. FPNs (effective diameter: 83.2 ± 1.1 nm; polydispersity index: 0.193) could significantly boost cellular accumulation of 5-FU and overcome the drug efflux mechanism of MDR than 5-FU-loaded NPNs and 5-FU in solution. In conclusion, ligand-targeted PNs can be used as a potentially effective drug delivery system.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Ferrocene Chemistry and Applications · Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN (2002) Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother 50:6–810.1007/s00280-002-0464-0 ↗
2. Chavanpatil MD, Khdair A, Gerard B, Bachmeier C, Miller DW, Shekhar MPV, Panyam J (2007) Surfactant-polymer nanoparticles overcome P-glycoprotein mediated drug efflux. Mol Pharm 4:730–73810.1021/mp070024d ↗
3. Dong XW, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ (2009) Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-Glycoprotein and depleting ATP. Cancer Res 69:3918–392610.1158/0008-5472.CAN-08-2747 ↗
4. Eliaz RE, Szoka FC (2001) Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 61:2592–2601
5. Fischer KE, Jayagopal A, Nagaraj G, Daniels R, Li E, Silvestrini M, Desai TA (2011) Nanoengineered surfaces enhance drug loading and adhesion. Nano Lett 11:1076–108110.1021/nl103951e ↗
6. Gabizon AA (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7:223–225
7. Gabizon A, Horowitz AT, Goren D, Tzemach D, Mandelbaum-Shavit F, Qazen MM, Zalipsky S (1999) Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 10:289–29810.1021/bc9801124 ↗
8. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S (2003) In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 9:6551–6559
9. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S (2004) Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177–119210.1016/j.addr.2004.01.011 ↗
10. Goren D, Horowitz AT, Tzemack D, Tarshish M, Zalipsky S, Gabizon A (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6:1949–1957
11. Grit M, DeSmidt JH, Struijke A, Crommelin DJA (1989) Hydrolysis of phosphatidylcholine in aqueous liposome dispersions. Int J Pharm 50:1–610.1016/0378-5173(89)90173-7 ↗
12. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1:297–31510.2217/17435889.1.3.297 ↗
13. Kabanov AV, Batrakova EV, Alakhov VY (2002) Pluronic ® block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 54:759–77910.1016/S0169-409X(02)00047-9 ↗
14. Kawano K, Onose E, Hattori Y, Maitani Y (2009) Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone. Mol Pharm 6:98–10410.1021/mp800069c ↗
15. Lee ES, Na K, Bae YH (2003) Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release 91:103–11310.1016/S0168-3659(03)00239-6 ↗
16. Liang XF, Wang HJ, Luo H, Tian H, Zhang BB, Hao LJ, Teng J, Chang J (2008) Characterization of novel multifunctional cationic polymeric liposomes formed from octadecyl quaternized carboxymethyl chitosan/cholesterol and drug encapsulation. Langmuir 24:7147–715310.1021/la703775a ↗
17. Liang XF, Tian H, Luo H, Wang HJ, Chang J (2009) Novel quaternized chitosan and polymeric micelles with cross-linked ionic cores for prolonged release. J Biomater Sci 20:115–13110.1163/156856208X393536 ↗
18. Liang XF, Li XY, Chang J, Duan YR, Li ZH (2013) Properties and evaluation of quaternized chitosan/lipid cation polymeric liposomes for cancer targeted gene delivery. Langmuir 29:8683–869310.1021/la401166v ↗
19. Maruyama K (2002) PEG-immunoliposome. Biosci Rep 22:251–26610.1023/A:1020138622686 ↗
20. Mohapatra S, Mallick SK, Maiti TK, Ghosh SK, Pramanik P (2007) Synthesis of highly stable folic acid conjugated magnetite nanoparticles for targeting cancer cells. Nanotechnology 18:385102–38511110.1088/0957-4484/18/38/385102 ↗
21. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC (2004) Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 8:335–35310.1517/14728222.8.4.335 ↗
22. Park JW (2002) Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4:95–9910.1186/bcr432 ↗
23. Schmidt HT, Ostafin AE (2002) Liposome directed growth of calcium phosphate nanoshells. Adv Mater 14:532–53510.1002/1521-4095(20020404)14:7<532::AID-ADMA532>3.0.CO;2-4 ↗
24. Tagalakis AD, Hyang DD, Bienemann AS, Zhou HY (2014) Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery. Biomaterials 35:8406–841510.1016/j.biomaterials.2014.06.003 ↗
25. Wang HJ, Zhao PQ, Liang XF, Gong XQ, Song T, Niu RF, Chang J (2010) Folate-PEG coated cationic modified chitosan-cholesterol liposomes for tumor-targeted drug delivery. Biomaterials 31:4129–413810.1016/j.biomaterials.2010.01.089 ↗
26. Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu ZS, Erhan SZ, Wu XY (2006) A new polymer-lipid hybrid nanoparticle system increase cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 23:1574–158510.1007/s11095-006-0282-x ↗
27. Zalipsky S, Brandeis E, Newman MS, Woodle MC (1994) Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett 353:71–7410.1016/0014-5793(94)01013-7 ↗
28. Zhang L, Granick S (2006) How to stabilize phospholipid liposomes (using nanoparticles). Nano Lett 6:694–69810.1021/nl052455y ↗
29. Zhigaltsev IV, Maurer N, Akhong QF, Leone R, Leng E, Wang J, Semple SC, Cullis PR (2005) Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 104:103–11110.1016/j.jconrel.2005.01.010 ↗